Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy

Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol te...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Yeongcheol Cheong [verfasserIn] Hidetoshi Katsuno [verfasserIn] Hiroshi Matsuoka [verfasserIn] Masahiro Mizuno [verfasserIn] Tomoyoshi Endo [verfasserIn] Tadahiro Kamiya [verfasserIn] Yosuke Tajima [verfasserIn] Keigo Ashida [verfasserIn] Yoshikazu Koide [verfasserIn] Koji Masumori [verfasserIn] Harunobu Sato [verfasserIn] Tsunekazu Hanai [verfasserIn] Kotaro Maeda [verfasserIn] Ichiro Uyama [verfasserIn] Junichiro Hiro [verfasserIn] Koichi Suda [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	menthol oxaliplatin-induced neuropathy opn oxaliplatin

Übergeordnetes Werk:	In: Fujita Medical Journal - Fujita Medical Society, 2020, 8(2022), 3, Seite 88-95
Übergeordnetes Werk:	volume:8 ; year:2022 ; number:3 ; pages:88-95

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.20407/fmj.2021-011

Katalog-ID:	DOAJ020026404

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ020026404
003	DE-627
005	20230307034141.0
007	cr uuu---uuuuu
008	230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.20407/fmj.2021-011 \|2 doi
035			\|a (DE-627)DOAJ020026404
035			\|a (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Yeongcheol Cheong \|e verfasserin \|4 aut
245	1	0	\|a Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.
650		4	\|a menthol
650		4	\|a oxaliplatin-induced neuropathy
650		4	\|a opn
650		4	\|a oxaliplatin
653		0	\|a Medicine (General)
700	0		\|a Hidetoshi Katsuno \|e verfasserin \|4 aut
700	0		\|a Hiroshi Matsuoka \|e verfasserin \|4 aut
700	0		\|a Masahiro Mizuno \|e verfasserin \|4 aut
700	0		\|a Tomoyoshi Endo \|e verfasserin \|4 aut
700	0		\|a Tadahiro Kamiya \|e verfasserin \|4 aut
700	0		\|a Yosuke Tajima \|e verfasserin \|4 aut
700	0		\|a Keigo Ashida \|e verfasserin \|4 aut
700	0		\|a Yoshikazu Koide \|e verfasserin \|4 aut
700	0		\|a Koji Masumori \|e verfasserin \|4 aut
700	0		\|a Harunobu Sato \|e verfasserin \|4 aut
700	0		\|a Tsunekazu Hanai \|e verfasserin \|4 aut
700	0		\|a Kotaro Maeda \|e verfasserin \|4 aut
700	0		\|a Ichiro Uyama \|e verfasserin \|4 aut
700	0		\|a Junichiro Hiro \|e verfasserin \|4 aut
700	0		\|a Koichi Suda \|e verfasserin \|4 aut
773	0	8	\|i In \|t Fujita Medical Journal \|d Fujita Medical Society, 2020 \|g 8(2022), 3, Seite 88-95 \|w (DE-627)1692251066 \|x 21897255 \|7 nnns
773	1	8	\|g volume:8 \|g year:2022 \|g number:3 \|g pages:88-95
856	4	0	\|u https://doi.org/10.20407/fmj.2021-011 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 \|z kostenfrei
856	4	0	\|u https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2189-7247 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2189-7255 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 8 \|j 2022 \|e 3 \|h 88-95

Indexfelder

author_variant	y c yc h k hk h m hm m m mm t e te t k tk y t yt k a ka y k yk k m km h s hs t h th k m km i u iu j h jh k s ks
matchkey_str	article:21897255:2022----::salsmnoteetotsaalnclvlainehdooa
hierarchy_sort_str	2022
callnumber-subject-code	R
publishDate	2022
allfields	10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95
spelling	10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95
allfields_unstemmed	10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95
allfieldsGer	10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95
allfieldsSound	10.20407/fmj.2021-011 doi (DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1 DE-627 ger DE-627 rakwb eng R5-920 Yeongcheol Cheong verfasserin aut Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage. menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General) Hidetoshi Katsuno verfasserin aut Hiroshi Matsuoka verfasserin aut Masahiro Mizuno verfasserin aut Tomoyoshi Endo verfasserin aut Tadahiro Kamiya verfasserin aut Yosuke Tajima verfasserin aut Keigo Ashida verfasserin aut Yoshikazu Koide verfasserin aut Koji Masumori verfasserin aut Harunobu Sato verfasserin aut Tsunekazu Hanai verfasserin aut Kotaro Maeda verfasserin aut Ichiro Uyama verfasserin aut Junichiro Hiro verfasserin aut Koichi Suda verfasserin aut In Fujita Medical Journal Fujita Medical Society, 2020 8(2022), 3, Seite 88-95 (DE-627)1692251066 21897255 nnns volume:8 year:2022 number:3 pages:88-95 https://doi.org/10.20407/fmj.2021-011 kostenfrei https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 kostenfrei https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en kostenfrei https://doaj.org/toc/2189-7247 Journal toc kostenfrei https://doaj.org/toc/2189-7255 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2022 3 88-95
language	English
source	In Fujita Medical Journal 8(2022), 3, Seite 88-95 volume:8 year:2022 number:3 pages:88-95
sourceStr	In Fujita Medical Journal 8(2022), 3, Seite 88-95 volume:8 year:2022 number:3 pages:88-95
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	menthol oxaliplatin-induced neuropathy opn oxaliplatin Medicine (General)
isfreeaccess_bool	true
container_title	Fujita Medical Journal
authorswithroles_txt_mv	Yeongcheol Cheong @@aut@@ Hidetoshi Katsuno @@aut@@ Hiroshi Matsuoka @@aut@@ Masahiro Mizuno @@aut@@ Tomoyoshi Endo @@aut@@ Tadahiro Kamiya @@aut@@ Yosuke Tajima @@aut@@ Keigo Ashida @@aut@@ Yoshikazu Koide @@aut@@ Koji Masumori @@aut@@ Harunobu Sato @@aut@@ Tsunekazu Hanai @@aut@@ Kotaro Maeda @@aut@@ Ichiro Uyama @@aut@@ Junichiro Hiro @@aut@@ Koichi Suda @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	1692251066
id	DOAJ020026404
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020026404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307034141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20407/fmj.2021-011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020026404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yeongcheol Cheong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">menthol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidetoshi Katsuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Matsuoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomoyoshi Endo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tadahiro Kamiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yosuke Tajima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keigo Ashida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshikazu Koide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masumori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harunobu Sato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tsunekazu Hanai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kotaro Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Uyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Junichiro Hiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koichi Suda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Fujita Medical Journal</subfield><subfield code="d">Fujita Medical Society, 2020</subfield><subfield code="g">8(2022), 3, Seite 88-95</subfield><subfield code="w">(DE-627)1692251066</subfield><subfield code="x">21897255</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:88-95</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20407/fmj.2021-011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7255</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">88-95</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Yeongcheol Cheong
spellingShingle	Yeongcheol Cheong misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General) Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
authorStr	Yeongcheol Cheong
ppnlink_with_tag_str_mv	@@773@@(DE-627)1692251066
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	21897255
topic_title	R5-920 Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy menthol oxaliplatin-induced neuropathy opn oxaliplatin
topic	misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General)
topic_unstemmed	misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General)
topic_browse	misc R5-920 misc menthol misc oxaliplatin-induced neuropathy misc opn misc oxaliplatin misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Fujita Medical Journal
hierarchy_parent_id	1692251066
hierarchy_top_title	Fujita Medical Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1692251066
title	Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
ctrlnum	(DE-627)DOAJ020026404 (DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1
title_full	Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
author_sort	Yeongcheol Cheong
journal	Fujita Medical Journal
journalStr	Fujita Medical Journal
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	88
author_browse	Yeongcheol Cheong Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda
container_volume	8
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Yeongcheol Cheong
doi_str_mv	10.20407/fmj.2021-011
author2-role	verfasserin
title_sort	establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
callnumber	R5-920
title_auth	Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
abstract	Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.
abstractGer	Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.
abstract_unstemmed	Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
url	https://doi.org/10.20407/fmj.2021-011 https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1 https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en https://doaj.org/toc/2189-7247 https://doaj.org/toc/2189-7255
remote_bool	true
author2	Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda
author2Str	Hidetoshi Katsuno Hiroshi Matsuoka Masahiro Mizuno Tomoyoshi Endo Tadahiro Kamiya Yosuke Tajima Keigo Ashida Yoshikazu Koide Koji Masumori Harunobu Sato Tsunekazu Hanai Kotaro Maeda Ichiro Uyama Junichiro Hiro Koichi Suda
ppnlink	1692251066
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.20407/fmj.2021-011
callnumber-a	R5-920
up_date	2024-07-04T01:50:02.371Z
_version_	1803611330182119424
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020026404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307034141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.20407/fmj.2021-011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020026404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ07f97b6445fb4834bb42a99bd14146d1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Yeongcheol Cheong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives: To determine whether the tongue menthol test, which measures the cold sensation detection threshold (CDT) of the tongue, used before and after oxaliplatin administration is an objective evaluation method for oxaliplatin-induced peripheral neuropathy (OPN). Methods: The tongue menthol test was administered to patients both before and after undergoing chemotherapy containing oxaliplatin for colorectal cancer. The tongue menthol test was conducted by applying a menthol solution (a selective agonist of transient receptor potential cation channel subfamily M member 8 [TRPM8]) to the tongue and measuring the CDT. Results: The mean CDT before the first dose of oxaliplatin was 0.34% (0.005%–1%; n=38), and the mean CDT after the first dose was 0.32% (0.005%–1%; n=38). The CDT appeared to decrease after the first dose, but this difference was not significant. In patients who received five courses of oxaliplatin, changes in CDT values were compared before and after the five courses. In patients with Neurotoxicity Criteria of Debiopharm (DEB-NTC) grade 2 neuropathy, the pre-oxaliplatin administration CDT was compared between before grade exacerbation and when exacerbation occurred, and was found to decline when grade exacerbation occurred. Moreover, when the CDTs before and after administration were compared before grade exacerbation, there was a significant decrease in CDT after administration (P=0.04). Conclusions: By performing a menthol test in oxaliplatin-treated patients, it may be possible to objectively predict the exacerbation of peripheral neuropathy at an early stage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">menthol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin-induced neuropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">opn</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxaliplatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hidetoshi Katsuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Matsuoka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masahiro Mizuno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomoyoshi Endo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tadahiro Kamiya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yosuke Tajima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Keigo Ashida</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshikazu Koide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koji Masumori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harunobu Sato</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tsunekazu Hanai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kotaro Maeda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ichiro Uyama</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Junichiro Hiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Koichi Suda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Fujita Medical Journal</subfield><subfield code="d">Fujita Medical Society, 2020</subfield><subfield code="g">8(2022), 3, Seite 88-95</subfield><subfield code="w">(DE-627)1692251066</subfield><subfield code="x">21897255</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:88-95</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.20407/fmj.2021-011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/07f97b6445fb4834bb42a99bd14146d1</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.jstage.jst.go.jp/article/fmj/8/3/8_2021-011/_pdf/-char/en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2189-7255</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="h">88-95</subfield></datafield></record></collection>
score	7.3996735

Nicht das Richtige dabei?

Schreiben Sie uns!

Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?